Retatrutide, weight loss, semaglutide, ozempic

Retatrutide, also known as “Triple G”, is THE new weight loss injection.  Semaglutide hits GLP-1, Tirzepatide targets GLP-1 and GIP, Retatrutide targets GLP-1 and GIP and Glucagon- giving it it’s name of “Triple G”.  This is currently the only injectable to target all three and is quickly becoming the latest craze in the injectable weight loss game!

Not only can you lose more weight faster with this option than with semaglutide or tirzepatide by up to 28%, but the drug also repairs fatty liver disease. In a Phase 2 clinical trial published in The New England Journal of Medicine, it achieved up to a 17.5% mean weight loss reduction at 24 weeks of use in overweight and obese adults.  While it is an investigational treatment for obesity, it works by targeting three different hunger-regulating hormones: GIP and GLP-1 which both stimulate cells in the pancreas to secrete insulin, and glucagon, which stimulates glucose production in the liver.

Retatrutide is in its final trial stages, meaning it is currently only available off-label, but demand is sure to skyrocket as soon as it is granted FDA approval. Call TBTW today to discuss this once-weekly injectable weight loss secret and be first in line to try this new weight loss weapon!

📞 (813) 609-4150

📧 insight@tbtotalwellness.com

Schedule Appointment